Cart is empty 
Overview
Tirzepatide is a synthetic peptide that functions as a dual agonist of the Glucose-Dependent Insulinotropic Polypeptide (GIP) receptor and the Glucagon-Like Peptide-1 (GLP-1) receptor. Research has focused on its effects on glucose metabolism, body composition, energy balance, insulin sensitivity, and metabolic regulation. Tirzepatide is considered a next-generation incretin-based compound due to its simultaneous activation of two metabolic hormone pathways.
Mechanism of Action
Research suggests Tirzepatide activates both GIP and GLP-1 receptors. Activation of these pathways influences insulin secretion, glucagon regulation, gastric emptying, appetite signaling, and energy metabolism. Studies have demonstrated significant effects on glycemic control, body weight regulation, and metabolic biomarkers through combined incretin receptor activation.
Compound Information
Stability Information
- Type: Dual Incretin Receptor Agonist
- Targets: GIP Receptor and GLP-1 Receptor
- Molecular Formula: C225H348N48O68
- Molecular Weight: 4813.5 g/mol
- Research Areas: Metabolism, glucose regulation, body composition, energy balance
- Room temperature stable (short-term)
- Protect from light
- Avoid repeated freeze-thaw cycles
- Lyophilized: Store at -20°C
- Reconstituted: Store at 2-8°C
Published Studies
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2).
- https://pubmed.ncbi.nlm.nih.gov/34186022/
- Thymosin beta4 promotes angiogenesis, wound healing, and hair growth in normal and aged rodents.
- Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4).
- https://pubmed.ncbi.nlm.nih.gov/35468325/
- Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2).
- Efficacy and Safety of Tirzepatide in Type 2 Diabetes: A Review of the SURPASS Program.
- A Post Hoc Assessment of the SURPASS Clinical Trial Program.
- Tirzepatide: Overview of Clinical Studies from the SURPASS and SURMOUNT Programs.
- Real-World Evaluation of Tirzepatide in Patients with Type 2 Diabetes.
Information provided for educational and research reference purposes only. Studies listed are third-party publications and do not constitute medical advice.